Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 268,432 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the sale, the chief financial officer now owns 1,032,754 shares in the company, valued at $4,141,343.54. The trade was a 20.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Shares of CKPT stock traded up $0.38 on Friday, reaching $3.75. 2,234,921 shares of the company's stock were exchanged, compared to its average volume of 675,598. The company's fifty day simple moving average is $3.57 and its 200 day simple moving average is $2.70. Checkpoint Therapeutics, Inc. has a 52 week low of $1.38 and a 52 week high of $4.50. The stock has a market capitalization of $183.12 million, a PE ratio of -2.04 and a beta of 1.34.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.08). As a group, sell-side analysts predict that Checkpoint Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Choreo LLC grew its position in shares of Checkpoint Therapeutics by 12.2% during the 2nd quarter. Choreo LLC now owns 65,002 shares of the company's stock worth $133,000 after buying an additional 7,080 shares in the last quarter. XTX Topco Ltd purchased a new stake in Checkpoint Therapeutics in the second quarter worth about $34,000. B. Riley Wealth Advisors Inc. lifted its stake in Checkpoint Therapeutics by 366.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company's stock worth $493,000 after acquiring an additional 180,050 shares during the period. PVG Asset Management Corp bought a new position in Checkpoint Therapeutics during the 2nd quarter worth about $295,000. Finally, Magnus Financial Group LLC increased its position in Checkpoint Therapeutics by 12.9% during the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company's stock valued at $78,000 after purchasing an additional 4,000 shares during the period. 22.00% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have recently weighed in on CKPT. Lake Street Capital increased their target price on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a "buy" rating in a research note on Monday. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a report on Monday.

View Our Latest Report on CKPT

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Checkpoint Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Checkpoint Therapeutics wasn't on the list.

While Checkpoint Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.